GSK to Acquire Efimosfermin, Enhancing SLD Treatment Portfolio
Deal News | May 14, 2025 | GSK PLC
GSK PLC is set to acquire efimosfermin, a drug that is in its phase III readiness to combat steatotic liver disease (SLD). This acquisition signals a strategic expansion of GSK's specialty medicines portfolio, poised to potentially offer a best-in-class solution for treating and halting the progression of SLD. The transaction marks GSK's dedication to advancing medical innovation and addressing unmet medical needs in liver disease management.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- United Kingdom – GSK PLC is based in the UK, making this a relevant geographic classification for the acquisition activity.
Industry
- Pharmaceuticals – The industry involves drug development and manufacturing, particularly relevant as GSK is acquiring a new drug for SLD treatment.
- Healthcare – This industry encompasses medical innovation and patient care, which is pertinent given the focus on advancing treatment for liver diseases.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| GSK PLC | Acquiring Company | Company | A British multinational pharmaceutical and biotechnology company involved in the acquisition of efimosfermin. |